SPOTLIGHT -
Identifying the bottlenecks that are preventing effective management of neovascular AMD.
Outlook Therapeutics submits UK Marketing Authorisation Application for wet AMD treatment
The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March
Updates From Angiogenesis-2022
ARVO 2024: Non-invasive testing could use tear film to screen for changes in Huntington Disease
The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease
Updates from ASRS 2021
ARVO 2024: Murine model of multiple sclerosis demonstrates correlation between visual markers and motor-sensory deficits
Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model
Espansione Group: Illuminating the Future of AMD Treatment: The Breakthrough of LightWave I Trial with PBM Technology